BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Papadimitriou L, Moore CK, Butler J, Long RC. The Limitations of Symptom-based Heart Failure Management. Card Fail Rev 2019;5:74-7. [PMID: 31179015 DOI: 10.15420/cfr.2019.3.2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Bunsawat K, Ratchford SM, Alpenglow JK, Park SH, Jarrett CL, Stehlik J, Smith AS, Richardson RS, Wray DW. Sacubitril-valsartan improves conduit vessel function and functional capacity and reduces inflammation in heart failure with reduced ejection fraction. J Appl Physiol (1985) 2021;130:256-68. [PMID: 33211601 DOI: 10.1152/japplphysiol.00454.2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Carrilho P. Intravenous iron in heart failure and chronic kidney disease. Nefrología (English Edition) 2021;41:403-11. [DOI: 10.1016/j.nefroe.2021.10.007] [Reference Citation Analysis]
3 Pepin ME, Ha CM, Potter LA, Bakshi S, Barchue JP, Haj Asaad A, Pogwizd SM, Pamboukian SV, Hidalgo BA, Vickers SM, Wende AR. Racial and socioeconomic disparity associates with differences in cardiac DNA methylation among men with end-stage heart failure. Am J Physiol Heart Circ Physiol 2021;320:H2066-79. [PMID: 33769919 DOI: 10.1152/ajpheart.00036.2021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Carrilho P. Intravenous iron in heart failure and chronic kidney disease. Nefrologia 2021;41:403-11. [PMID: 33250198 DOI: 10.1016/j.nefro.2020.07.009] [Reference Citation Analysis]
5 Liu Y, Hao C, Zhang W, Liu Y, Guo S, Li R, Peng M, Xu Y, Pei X, Yang H, Zhao Y. Leucine-rich repeat kinase-2 deficiency protected against cardiac remodelling in mice via regulating autophagy formation and degradation. Journal of Advanced Research 2021. [DOI: 10.1016/j.jare.2021.07.004] [Reference Citation Analysis]